A bisphosphonate that inhibits bone resorption
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Zoledronic Acid (hydrate)

Item No. 14984

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
P,P'-[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-phosphonic acid, monohydrate
CAS Number
165800-06-6
Molecular Formula
C5H10N2O7P2 • H2O
Formula Weight
290.1
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
PBS (pH 7.2): 1.6 mg/ml
SMILES
OP(C(O)(P(O)(O)=O)CN1C=NC=C1)(O)=O.O
InChi Code
InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2
InChi Key
FUXFIVRTGHOMSO-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 mg

    $75

    Add

    50 mg

    $134

    Add

    100 mg

    $238

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Zoledronic acid is a third-generation heterocyclic nitrogen-containing bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption.1 It has a high affinity for hydroxyapatite (Ki = 3.47 μM) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis.2,1 At μM concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis.1 Zoledronic acid has been used in the treatment of osteoporosis, Paget’s disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.1,3,4,5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Li, E.C., and David, L.E. Zoledronic acid: A new parenteral bisphosphonate. Clin. Ther. 25(11), 2669-2708 (2003).

    2. Nancollas, G.H., Tang, R., Phipps, R.J., et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38(5), 617-627 (2006).

    3. Räkel, A., Boucher, A., and Ste-Marie, L.G. Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin. Interv. Aging 6, 89-99 (2011).

    4. El-Amm, J., Freeman, A., Patel, N., et al. Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigms. Prostate Cancer 2013, 1-10 (2013).

    5. Major, P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7(6), 481-491 (2002).

    6. Michou, L., and Brown, J.P. Emerging strategies and therapies for treatment of Paget’s disease of bone. Drug Des. Devel. Ther. 5, 225-239 (2011).